242 related articles for article (PubMed ID: 18447597)
1. New tubulin targeting agents currently in clinical development.
Carlson RO
Expert Opin Investig Drugs; 2008 May; 17(5):707-22. PubMed ID: 18447597
[TBL] [Abstract][Full Text] [Related]
2. Microtubule Targeting Agents as Cancer Chemotherapeutics: An Overview of Molecular Hybrids as Stabilizing and Destabilizing Agents.
Tangutur AD; Kumar D; Krishna KV; Kantevari S
Curr Top Med Chem; 2017; 17(22):2523-2537. PubMed ID: 28056738
[TBL] [Abstract][Full Text] [Related]
3. Targeting the microtubules in breast cancer beyond taxanes: the epothilones.
Cortes J; Baselga J
Oncologist; 2007 Mar; 12(3):271-80. PubMed ID: 17405891
[TBL] [Abstract][Full Text] [Related]
4. Tubulin inhibitors: a patent review.
Liu YM; Chen HL; Lee HY; Liou JP
Expert Opin Ther Pat; 2014 Jan; 24(1):69-88. PubMed ID: 24313741
[TBL] [Abstract][Full Text] [Related]
5. Development of other microtubule-stabilizer families: the epothilones and their derivatives.
Brogdon CF; Lee FY; Canetta RM
Anticancer Drugs; 2014 May; 25(5):599-609. PubMed ID: 24398663
[TBL] [Abstract][Full Text] [Related]
6. YSL-12, a novel microtubule-destabilizing agent, exerts potent anti-tumor activity against colon cancer in vitro and in vivo.
Cai D; Qiu Z; Yao W; Liu Y; Huang H; Liao S; Luo Q; Xie L; Lin Z
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1217-29. PubMed ID: 27107592
[TBL] [Abstract][Full Text] [Related]
7. Microtubules: a dynamic target in cancer therapy.
Pasquier E; Kavallaris M
IUBMB Life; 2008 Mar; 60(3):165-70. PubMed ID: 18380008
[TBL] [Abstract][Full Text] [Related]
8. Revisiting microtubule targeting agents: α-Tubulin and the pironetin binding site as unexplored targets for cancer therapeutics.
Coulup SK; Georg GI
Bioorg Med Chem Lett; 2019 Aug; 29(15):1865-1873. PubMed ID: 31130264
[TBL] [Abstract][Full Text] [Related]
9. Pyrrolotetrazinones deazaanalogues of temozolomide induce apoptosis in Jurkat cell line: involvement of tubulin polymerization inhibition.
Viola G; Cecconet L; Leszl A; Basso G; Brun P; Salvador A; Dall'Acqua F; Diana P; Barraja P; Cirrincione G
Cancer Chemother Pharmacol; 2009 Nov; 64(6):1235-51. PubMed ID: 19363609
[TBL] [Abstract][Full Text] [Related]
10. Discovery of a Series of Acridinones as Mechanism-Based Tubulin Assembly Inhibitors with Anticancer Activity.
Magalhaes LG; Marques FB; da Fonseca MB; Rogério KR; Graebin CS; Andricopulo AD
PLoS One; 2016; 11(8):e0160842. PubMed ID: 27508497
[TBL] [Abstract][Full Text] [Related]
11. Development of novel derivatives of stilbene and macrocyclic compounds as potent of anti-microtubule factors.
Borys F; Tobiasz P; Poterała M; Krawczyk H
Biomed Pharmacother; 2021 Jan; 133():110973. PubMed ID: 33378993
[TBL] [Abstract][Full Text] [Related]
12. Epothilones: a novel class of microtubule-stabilizing drugs for the treatment of cancer.
Trivedi M; Budihardjo I; Loureiro K; Reid TR; Ma JD
Future Oncol; 2008 Aug; 4(4):483-500. PubMed ID: 18684060
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and biological evaluation of a novel tubulin inhibitor 7a3 targeting the colchicine binding site.
Lai Q; Wang Y; Wang R; Lai W; Tang L; Tao Y; Liu Y; Zhang R; Huang L; Xiang H; Zeng S; Gou L; Chen H; Yao Y; Yang J
Eur J Med Chem; 2018 Aug; 156():162-179. PubMed ID: 30006162
[TBL] [Abstract][Full Text] [Related]
14. Tubulin: an example of targeted chemotherapy.
Seligmann J; Twelves C
Future Med Chem; 2013 Mar; 5(3):339-52. PubMed ID: 23464522
[TBL] [Abstract][Full Text] [Related]
15. Sterically induced conformational restriction: Discovery and preclinical evaluation of novel pyrrolo[3,2-d]pyrimidines as microtubule targeting agents.
Pavana RK; Shah K; Gentile T; Dybdal-Hargreaves NF; Risinger AL; Mooberry SL; Hamel E; Gangjee A
Bioorg Med Chem; 2018 Nov; 26(20):5470-5478. PubMed ID: 30297118
[TBL] [Abstract][Full Text] [Related]
16. A novel synthetic compound exerts effective anti-tumour activity in vivo via the inhibition of tubulin polymerisation in A549 cells.
Yan J; Pang Y; Sheng J; Wang Y; Chen J; Hu J; Huang L; Li X
Biochem Pharmacol; 2015 Sep; 97(1):51-61. PubMed ID: 26212540
[TBL] [Abstract][Full Text] [Related]
17. [Progress in the study of tubulin inhibitors].
Shang H; Pan L; Yang S; Chen H; Cheng MS
Yao Xue Xue Bao; 2010 Sep; 45(9):1078-88. PubMed ID: 21351562
[TBL] [Abstract][Full Text] [Related]
18. Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance.
Perez EA
Mol Cancer Ther; 2009 Aug; 8(8):2086-95. PubMed ID: 19671735
[TBL] [Abstract][Full Text] [Related]
19. Discovery of potent cytotoxic ortho-aryl chalcones as new scaffold targeting tubulin and mitosis with affinity-based fluorescence.
Zhu C; Zuo Y; Wang R; Liang B; Yue X; Wen G; Shang N; Huang L; Chen Y; Du J; Bu X
J Med Chem; 2014 Aug; 57(15):6364-82. PubMed ID: 25061803
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, biological evaluation, and 3D-QSAR analysis of podophyllotoxin-dioxazole combination as tubulin targeting anticancer agents.
Wang ZZ; Sun WX; Wang X; Zhang YH; Qiu HY; Qi JL; Pang YJ; Lu GH; Wang XM; Yu FG; Yang YH
Chem Biol Drug Des; 2017 Aug; 90(2):236-243. PubMed ID: 28079286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
